At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRBU Caribou Biosciences
Post-Market Trading 11-22 18:08:00 EST
2.02
+0.04
+2.02%
盘后2.03
+0.01+0.46%
17:33 EST
High2.05
Low1.93
Vol989.18K
Open1.98
D1 Closing1.98
Amplitude5.98%
Mkt Cap182.92M
Tradable Cap164.79M
Total Shares90.55M
T/O1.99M
T/O Rate1.21%
Tradable Shares81.58M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Caribou Biosciences to Participate in Upcoming Investor Conferences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.